Senesco Announces Additional $1.0 Million Equity Financing
02 Marzo 2012 - 7:30AM
Business Wire
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE
AMEX: SNT) announced today that it has entered into a securities
purchase agreement to raise an additional $1.0 million in gross
proceeds through the sale of 3,846,154 shares of its common stock.
The investor will also receive 50% warrant coverage at an exercise
price of $0.286 per share. The common stock and 50% warrant
coverage (the “Unit”) was priced at $0.26 per Unit.
The follow-on to the January 2012 offering is expected to close
on or about March 6, 2012. The net proceeds of the financing will
be used primarily for working capital, research and development and
general corporate purposes.
“We are very pleased that an investor in the previous round of
financing in January 2012 wanted to invest additional funds that
are now available,” said Leslie J. Browne, Ph.D., President and CEO
of Senesco. “The result with this financing is that the January
raise has rounded out at a total of approximately $3.0
million.”
The shares and warrants are being offered pursuant to a
prospectus forming a part of the Company’s effective registration
statement (File No. 333-170140) filed with the Securities and
Exchange Commission (the “SEC”), a copy of which may be obtained,
when available, at the SEC’s website at http://www.sec.gov.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy, nor will there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
Additional terms of this offering (including the full terms and
conditions of the securities purchase agreement and warrants) were
disclosed on a Form 8-K filed with the SEC by Senesco
simultaneously with this press release and will also be disclosed
in the prospectus filed with the SEC in connection with this
offering.
About Senesco Technologies, Inc.
Senesco, a leader in eIF5A technology, is running a clinical
study in multiple myeloma with its lead therapeutic candidate
SNS01-T, which targets B-cell cancers by selectively inducing
apoptosis by modulating eukaryotic, translation, initiation Factor
5A (eIF5A), which is believed to be an important regulator of cell
growth and cell death. Accelerating apoptosis may have applications
in treating cancer, while delaying apoptosis may have applications
in treating certain inflammatory and ischemic diseases. Senesco has
already partnered with leading-edge companies engaged in
agricultural biotechnology and biofuels development and is entitled
to earn research and development milestones and royalties if its
gene-regulating platform technology is incorporated into its
partners’ products.
About Multiple Myeloma
Multiple myeloma is an incurable cancer of plasma cells, a type
of white blood cell derived from B-lymphocytes, normally
responsible for the production of antibodies. Senesco was
previously granted orphan drug status for SNS01-T, the Company’s
lead drug candidate for treatment of multiple myeloma.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company's license agreements; the acceptance by the
market of the Company’s products; the timing and success of the
Company’s preliminary studies, preclinical research and clinical
trials; competition and the timing of projects and trends in future
operating performance, the Company’s ability to comply with the
continued listing standards of the NYSE Amex, as well as other
factors expressed from time to time in the Company’s periodic
filings with the SEC. As a result, this press release should be
read in conjunction with the Company’s periodic filings with the
SEC. The forward-looking statements contained herein are made only
as of the date of this press release, and the Company undertakes no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
Senesco (AMEX:SNT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Senesco (AMEX:SNT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024